Article
Debugging the Black Box.
Cancer discovery - 1 Mar 2017
Yang James C
Abstract excerpt
<b/> A better understanding of the mechanisms by which tumor rejection succeeds and fails is needed to improve immunotherapies. Here, Anagnostou and colleagues find that mutations predicted to be the most immunogenic are preferentially lost when cancer progresses through checkpoint blockade. Cancer Discov; 7(3); 250-1. ©2017 AACRSee related article by Anagnostou et al., p. 264.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.